King Altace
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee votes unanimously May 1 that a pivotal study of ramipril demonstrated a beneficial effect for the combined endpoint of myocardial infarction (MI), stroke and death from cardiovascular events. In a study of patients at risk of cardiovascular events, the combined endpoint was met by 14% of ramipril patients (651 of 4,645 patients) versus 17.8% of placebo patients (826 of 4,652) with a relative risk of 0.78 (0.70-0.86 95% CI, p<0.001). The committee voted five to four not to approve a claim that ramipril decreases the need for coronary revascularization, saying it might not be an appropriate type of claim. Revascularization was required in 16% of ramipril patients and 18.4% of placebo patients. King told the committee that "the only adverse event is a 5% excess of cough" between ramipril patients (7.3%) and placebo patients (1.8%). Altace is currently indicated for treatment of hypertension and for treatment of heart failure following MI
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.